In addition, considering the ability of our preclinical CMS3 models to reflect transcriptomic pattern of CMS3 tumor samples, it can be assumed that patients with CMS3 tumors would most benefit from treatment with CAIX/XII-specific inhibitors such as SLC-0111. Here, CA9 is linked to neoplasm.